bioMerieux SA to Develop New Highly-Specific, Non-Invasive Test for Prostate Cancer, Reducing Unnecessary Biopsies
9/25/2008 8:53:27 AM
MARCY L'ETOILE, France--(BUSINESS WIRE)--
Prostate cancer is the most prevalent cancer in the United States and the 4th most common worldwide. The combination of a test for a new prostate cancer biomarker, Annexin 3, with the standard screening methods could potentially reduce the number of biopsies conducted by up to 75%, when compared with current screening methods alone. A world leader in the field of in vitro diagnostics, bioMérieux has signed a license and development agreement with the German biotechnology company, ProteoSys, for Annexin 3, which will be used to develop a urine-based, confirmatory diagnostic test for prostate cancer. After a research phase, the new test should be developed on the VIDAS® platform, one of the most widely installed automated immunoassay instruments in the world.
comments powered by